These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1165 related articles for article (PubMed ID: 29074603)

  • 21. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
    Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
    Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
    Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
    Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 28. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
    Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
    Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
    Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.
    Hospital MA; Green AS; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Blood; 2012 Feb; 119(7):1791-2. PubMed ID: 22343664
    [No Abstract]   [Full Text] [Related]  

  • 32. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
    Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
    Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 34. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
    Yoshida A; Ookura M; Zokumasu K; Ueda T
    Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C; Zhang Y; Yang J; Xu Y; Deng T; Li Y; Xu S; Wang S; Wang P
    Cell Commun Signal; 2024 Jul; 22(1):355. PubMed ID: 38978049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
    Sexauer A; Perl A; Yang X; Borowitz M; Gocke C; Rajkhowa T; Thiede C; Frattini M; Nybakken GE; Pratz K; Karp J; Smith BD; Levis M
    Blood; 2012 Nov; 120(20):4205-14. PubMed ID: 23012328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
    Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
    Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
    Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.
    Gebru MT; Atkinson JM; Young MM; Zhang L; Tang Z; Liu Z; Lu P; Dower CM; Chen L; Annageldiyev C; Sharma A; Imamura Kawasawa Y; Zhao Z; Miller BA; Claxton DF; Wang HG
    Blood; 2020 Aug; 136(9):1067-1079. PubMed ID: 32396937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.